Skip to main content
. 2022 Jan 4;12:803363. doi: 10.3389/fendo.2021.803363

Figure 1.

Figure 1

Effect of liraglutide and β3-AR stimulation on fasting blood glucose, body weight, fat mass, and food intake. (A) Study design: male C57BL/6J received liraglutide (400 μg/kg/d) or control for 21 days, ± the β3-adrenergic agonist CL 316,243 (CL) during the last 5 days of treatment. (B) Fasting blood glucose levels after liraglutide and CL treatment, (C) body weight before and during liraglutide and CL treatment, (D) body weight change after liraglutide and CL treatment, (E) energy intake before and during liraglutide and CL treatment, (F) mean daily energy intake during liraglutide and CL treatment, (G) caloric efficiency, and (H) iBAT, (I) ingWAT, and (J) epiWAT mass. #p < 0.05 liraglutide-treated mice (Lira and Lira + CL) vs vehicle by Two-way ANOVA followed by Tukey’s multiple comparison test. *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001 vs control or indicated group, by One-way ANOVA followed by Tukey’s multiple comparison test. Data presented as mean ± SEM, n=5-6 for each experimental group. CL, CL316,243; epiWAT, epidydimal white adipose tissue; iBAT, interscapular brown adipose tissue; ingWAT, inguinal white adipose tissue; Lira, liraglutide.